ImmunityBio (IBRX) Stock Price, News & Analysis

Company Overview

ImmunityBio, Inc. is a clinical-stage biotechnology company dedicated to developing targeted immunotherapies for cancer and infectious diseases. The company leverages a proprietary platform of natural killer (NK) cell and T-cell therapies, oncolytic adenovirus technology and an Artificial Intelligence RNA (AiR) mRNA platform to stimulate and enhance the body’s immune response. ImmunityBio’s research focuses on multiplexed approaches designed to overcome tumor microenvironment resistance and drive more durable clinical responses.

The company’s pipeline includes several lead product candidates across solid tumors and viral diseases. Its NK-cell therapy programs are engineered to persist and expand in vivo, offering potential treatment options for indications such as head and neck cancer, non-small cell lung cancer and melanoma. Complementing cell therapies, ImmunityBio’s oncolytic adenovirus platform delivers immune-activating cytokines directly to tumor sites, while its AiR mRNA vaccine technology is being applied to both emerging infectious diseases and oncology settings.

Founded in 2014 under the name NantKwest and rebranded as ImmunityBio in 2021, the company is headquartered in Culver City, California. ImmunityBio was established by entrepreneur and physician Patrick Soon-Shiong, who serves as Executive Chairman. Under his leadership, the company has built collaborations with academic institutions and government agencies, including the U.S. National Institutes of Health, to advance clinical trials and co-develop next-generation immunotherapies.

ImmunityBio conducts its research and clinical programs primarily in the United States but has extended its footprint through international studies in South Africa and Asia. With a multidisciplinary leadership team of immunologists, oncology researchers and biomanufacturing experts, the company aims to translate scientific innovation into scalable treatments that address unmet medical needs across diverse patient populations.

Key Stats

• Today's Range: $2.80 to $2.95
• 50-Day Range: $1.89 to $3.44
• 52-Week Range: $1.83 to $7.48
• Volume: 6.02 million shs
• Average Volume: 6.27 million shs
• Market Capitalization: $2.48 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.25
• Consensus Rating: Buy

ImmunityBio Stock Analysis - MarketRank™

ImmunityBio scored higher than 47% of companies evaluated by MarketBeat, and ranked 567th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

ImmunityBio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ImmunityBio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImmunityBio are expected to grow in the coming year, from ($0.92) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunityBio is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunityBio is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

37.57% of the float of ImmunityBio has been sold short.

Short Interest Ratio / Days to Cover

ImmunityBio has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in ImmunityBio has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunityBio does not currently pay a dividend.

Dividend Growth

ImmunityBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

37.57% of the float of ImmunityBio has been sold short.

Short Interest Ratio / Days to Cover

ImmunityBio has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in ImmunityBio has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.35

News Sentiment

ImmunityBio has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for ImmunityBio this week, compared to 4 articles on an average week.

Search Interest

17 people have searched for IBRX on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.

MarketBeat Follows

17 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is an increase of 42% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmunityBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

76.79% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.58% of the stock of ImmunityBio is held by institutions.

IBRX Stock Analysis - Frequently Asked Questions

How have IBRX shares performed this year?

ImmunityBio's stock was trading at $2.56 at the start of the year. Since then, IBRX stock has increased by 9.8% and is now trading at $2.81.

How were ImmunityBio's earnings last quarter?

ImmunityBio, Inc. (NASDAQ:IBRX) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The firm earned $16.52 million during the quarter, compared to analysts' expectations of $17.50 million.

Who are ImmunityBio's major shareholders?

ImmunityBio's top institutional investors include Wealth Management Partners LLC, Wealth Enhancement Advisory Services LLC and Thrive Wealth Management LLC. Insiders that own company stock include Michael D Blaszyk and John Owen Brennan.
View institutional ownership trends.

How do I buy shares of ImmunityBio?

Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ImmunityBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunityBio investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Home Depot (HD), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IBRX
• CIK: 1326110
• Web: immunitybio.com
• Phone: (858) 633-0300
• Fax: N/A
• Employees: 590
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ImmunityBio: $12.25
• High Price Target: $30.00
• Low Price Target: $5.00
• Potential Upside/Downside: +335.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$413.56 million
• Net Margins: -1,310.30%
• Pretax Margin: -1,311.30%
• Return on Equity: N/A
• Return on Assets: -121.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.22
• Quick Ratio: 2.05

Sales & Book Value

• Annual Sales: $14.74 million
• Price / Sales: 168.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.57) per share
• Price / Book: -4.93

Miscellaneous

• Outstanding Shares: 882,620,000
• Free Float: 204,856,000
• Market Cap: $2.48 billion
• Optionable: Optionable
• Beta: 0.08